Open this publication in new window or tab >>Department of Clinical Science, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Science, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Stockholm, Sweden.
Department of Cardiology, Clinical Sciences, Lunds Universitet, Lund, Sweden.
Department of Cardiology, Clinical Sciences, Lunds Universitet, Lund, Sweden.
Medical Sciences, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala, Sweden.
Department of Cardiology Department of Health, Medicine and Caring Sciences, Linköping University, Linkoping, Sweden.
Projects, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Uppsala Clinical Research Center, Uppsala, Sweden.
Medical Sciences, Uppsala University, Uppsala, Sweden.
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Cardiology.
Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Global Medical Affairs, Respiratory, BioPharmaceutical Medical, AstraZeneca plc, London, UK.
Clinical Operations - Late Respiratory and Immunology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Cardiovascular Research Unit, The University of Sheffield, Sheffield, UK; NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Medical Sciences, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala, Sweden.
Show others...
2025 (English)In: BMJ Open, E-ISSN 2044-6055, Vol. 15, no 5, article id e097851Article in journal (Refereed) Published
Abstract [en]
OBJECTIVES: To establish the prevalence of clinically significant chronic obstructive pulmonary disease (COPD) and relevant characteristics in individuals with a significant smoking history who are hospitalised for acute myocardial infarction (MI).
DESIGN: Cross-sectional study.
SETTING: Hospital inpatients at 8 European centres (7 in Sweden, 1 in the UK). PARTICIPANTS: 518 men or women (302 in Sweden, 216 in the UK) hospitalised for acute MI, aged 40 years or older, with a smoking history of at least 10 pack-years.
PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was prevalence of detected significant COPD (Global Initiative for Chronic Obstructive Lung Disease stages 2-4), defined as a ratio of forced expiratory volume in 1 and 6 s (FEV1/FEV6) <0.7 and FEV1 <80% of the predicted value, measured using microspirometry. Secondary outcome measures were prior diagnosis of COPD, prescription of inhaled corticosteroids (ICS), symptom burden (COPD Assessment Test (CAT)) and blood eosinophil count.
RESULTS: The prevalence of significant COPD was 91/518 (18% (95% CI 14 to 21)) with no difference between the countries. Of those with detected significant COPD, 69 (76%) had no previous COPD diagnosis. A CAT score >10 was found in 65%, and a blood eosinophil count of ≥100/mm3 and ≥300/mm3 was found in 76% and 20%, respectively. Inhaled corticosteroids were used by 15% of the patients.
CONCLUSIONS: In a cohort of patients hospitalised for acute MI in Sweden and the UK, one in five patients with a history of smoking was found to have significant COPD based on microspirometry. Symptom burden was high and treatment rates with ICS low. Among those diagnosed with COPD, three out of four had not been previously diagnosed with COPD.
Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2025
Keywords
Epidemiology, Myocardial infarction, Pulmonary Disease, Chronic Obstructive, Respiratory Function Test
National Category
Respiratory Medicine and Allergy
Identifiers
urn:nbn:se:oru:diva-120998 (URN)10.1136/bmjopen-2024-097851 (DOI)001486578100001 ()40345691 (PubMedID)2-s2.0-105005029913 (Scopus ID)
Funder
AstraZeneca
2025-05-122025-05-122025-05-22Bibliographically approved